← Back to Search

TIGIT Inhibitor

COM902 for Cancer

Phase 1
Recruiting
Research Sponsored by Compugen Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Platinum resistant ovarian cancer (PROC) defined as disease recurrence < 6 months after completion of a platinum-containing regimen: Patients with primary platinum refractory disease are ineligible. Primary platinum refractory disease is defined as progression of disease prior to completion of 1st line platinum therapy or immediately following (≤ 3 months following last date of chemotherapy)
Subjects who have received PARP inhibitor therapy are eligible
Must not have
Prior treatment with an anti-PD-1/PD-L1/2, anti-CD96 antibody, anti-OX-40 antibody, anti-CD137 antibody, anti-LAG3, anti-TIM3, anti-CTLA4 antibody
Prior treatment with an inhibitor of PVRIG
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This trial is testing a new cancer drug, COM902, to see if it is safe and works well against cancer.

Who is the study for?
This trial is for adults with advanced cancers like ovarian, colon, or lung cancer who've tried standard treatments without success. They should be in relatively good physical condition (ECOG 0-1) and have had no more than three prior treatment lines. People with certain immune conditions or those previously treated with specific immunotherapies are not eligible.
What is being tested?
The study tests COM902 alone and in combinations: as a monotherapy, paired with COM701, and alongside both COM701 and Pembrolizumab. It's to see how safe they are and if they can shrink tumors. The doses will increase until researchers find the highest dose patients can take without serious side effects.
What are the potential side effects?
Potential side effects include reactions related to the immune system such as inflammation of organs, skin issues, fatigue, possible infusion-related reactions similar to allergic responses, and an increased risk of infections due to immune suppression.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My ovarian cancer came back less than 6 months after platinum treatment.
Select...
I have received PARP inhibitor therapy.
Select...
My condition is at stage IV.
Select...
I am fully active or can carry out light work.
Select...
My cancer is a type of colon/rectum cancer confirmed by lab tests.
Select...
I have an advanced cancer and have tried all standard treatments or can't receive them.
Select...
My condition worsened after 3 or fewer treatments including specific chemotherapy drugs.
Select...
My colorectal cancer is MSS as confirmed by an approved test.
Select...
I have advanced cancer in my ovary, fallopian tube, or the lining of my abdomen.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have previously been treated with specific immune-targeting medications.
Select...
I have been treated with a PVRIG inhibitor before.
Select...
I have been treated with a TIGIT inhibitor before.
Select...
I have lung inflammation or disease causing symptoms.
Select...
I stopped immunotherapy due to an immune-related side effect.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Evaluation of safety and tolerability of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).
The safety and tolerability of COM902 monotherapy and in combination with COM701.
+2 more
Secondary study objectives
To characterize immunogenicity of COM902 monotherapy and in combination with COM701.
To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Other study objectives
Evaluation of the preliminary antitumor activity of COM902 as monotherapy and in combination with COM701.
Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).

Side effects data

From 2022 Phase 1 & 2 trial • 35 Patients • NCT03003468
40%
FATIGUE
37%
INFUSION RELATED REACTION
37%
NAUSEA
23%
DIARRHEA
23%
BACK PAIN
23%
ABDOMINAL PAIN
23%
ANOREXIA
20%
ARTHRALGIA
20%
COUGH
20%
NON-CARDIAC CHEST PAIN
17%
DYSPNEA
17%
CONSTIPATION
17%
CHILLS
17%
MYALGIA
13%
DIZZINESS
13%
HEADACHE
13%
PRURITUS
13%
RASH MACULO-PAPULAR
10%
ANEMIA
10%
URTICARIA
10%
SINUS TACHYCARDIA
10%
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, SPECIFY
10%
EDEMA LIMBS
10%
ALLERGIC REACTION
10%
ANXIETY
10%
LUNG INFECTION
10%
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - OTHER, SPECIFY
7%
TUMOR PAIN
7%
EAR AND LABYRINTH DISORDERS - OTHER, SPECIFY
7%
HYPERGLYCEMIA
7%
PAIN
7%
PELVIC PAIN
7%
PRODUCTIVE COUGH
7%
PLEURAL EFFUSION
7%
VOICE ALTERATION
7%
VOMITING
7%
FEVER
7%
FLATULENCE
7%
CREATININE INCREASED
7%
HYPERTHYROIDISM
7%
NECK PAIN
7%
DEPRESSION
7%
FLU LIKE SYMPTOMS
7%
LYMPHOCYTE COUNT DECREASED
7%
DYSPEPSIA
7%
FLUSHING
7%
HYPONATREMIA
7%
HYPOTHYROIDISM
7%
URINARY TRACT INFECTION
3%
MUSCLE WEAKNESS LOWER LIMB
3%
ALKALINE PHOSPHATASE INCREASED
3%
DYSPHAGIA
3%
ESOPHAGITIS
3%
GASTROESOPHAGEAL REFLUX DISEASE
3%
OSTEONECROSIS OF JAW
3%
BRONCHOSPASM
3%
PNEUMONITIS
3%
SORE THROAT
3%
BLURRED VISION
3%
GAIT DISTURBANCE
3%
HEMORRHOIDS
3%
POSTNASAL DRIP
3%
PRESYNCOPE
3%
ACUTE KIDNEY INJURY
3%
PERIPHERAL MOTOR NEUROPATHY
3%
DRY SKIN
3%
FLASHING LIGHTS
3%
HYPOMAGNESEMIA
3%
HYPERTENSION
3%
HYPOTENSION
3%
SINUSITIS
3%
SYNCOPE
3%
HEARING IMPAIRED
3%
RASH ACNEIFORM
3%
SOMNOLENCE
3%
COLITIS
3%
HOT FLASHES
3%
RESPIRATORY FAILURE
3%
CONJUNCTIVITIS
3%
MOVEMENTS INVOLUNTARY
3%
NASAL CONGESTION
3%
PARESTHESIA
3%
VAGINAL INFECTION
3%
GASTROINTESTINAL DISORDERS - OTHER, SPECIFY
3%
NEUTROPHIL COUNT DECREASED
3%
ALLERGIC RHINITIS
3%
PAIN IN EXTREMITY
3%
SEPSIS
3%
BLOATING
3%
DEHYDRATION
3%
DRY MOUTH
3%
INSOMNIA
3%
MALAISE
3%
PAIN OF SKIN
3%
THROMBOEMBOLIC EVENT
3%
TREMOR
3%
WEIGHT GAIN
100%
80%
60%
40%
20%
0%
Study treatment Arm
Imprime PGG 4 mg/kg
Imprime PGG 2 mg/kg

Trial Design

6Treatment groups
Experimental Treatment
Group I: Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).Experimental Treatment1 Intervention
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC. All study drugs will be administered IV every 3 weeks.
Group II: MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).Experimental Treatment1 Intervention
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC. All study drugs will be administered IV every 3 weeks.
Group III: Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).Experimental Treatment1 Intervention
COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks.
Group IV: COM902 monotherapy dose escalation.Experimental Treatment1 Intervention
Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
Group V: COM902 monotherapy cohort expansion at RDFE.Experimental Treatment1 Intervention
COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
Group VI: COM902 + COM701 combination cohort expansion both at RDFE.Experimental Treatment1 Intervention
COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.

Find a Location

Who is running the clinical trial?

Compugen LtdLead Sponsor
2 Previous Clinical Trials
169 Total Patients Enrolled
COM902 Study Director COM902 Study DirectorStudy DirectorCompugen Ltd

Media Library

COM902 (TIGIT Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04354246 — Phase 1
Colon Cancer Research Study Groups: COM902 + COM701 combination cohort expansion both at RDFE., COM902 monotherapy dose escalation., MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab)., Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab)., COM902 monotherapy cohort expansion at RDFE., Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).
Colon Cancer Clinical Trial 2023: COM902 Highlights & Side Effects. Trial Name: NCT04354246 — Phase 1
COM902 (TIGIT Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04354246 — Phase 1
~6 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top